Premium
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability
Author(s) -
Williams H.,
Clarke R.,
Bouras N.,
Martin J.,
Holt G.
Publication year - 2000
Publication title -
journal of intellectual disability research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.941
H-Index - 104
eISSN - 1365-2788
pISSN - 0964-2633
DOI - 10.1046/j.1365-2788.2000.00284.x
Subject(s) - risperidone , olanzapine , intellectual disability , tolerability , psychiatry , atypical antipsychotic , antipsychotic , psychology , pediatrics , medicine , schizophrenia (object oriented programming) , adverse effect
The present study was designed to monitor the use of atypical antipsychotics in adults with intellectual disability and to evaluate the clinical effectiveness of these drugs. Twenty‐one patients were commenced on an atypical antipsychotic: 12 on Olanzapine and nine on Risperidone. The ICD‐10 diagnoses of the subjects were mild (13 cases) or moderate (8 cases) mental retardation, and psychiatric disorders (17 cases) with significant impairment of behaviour in 10 cases. Tolerability was good for 15 patients experiencing minimum or no side‐effects, and medication was only stopped as a result of side‐effects in one case. Clinical global outcome was rated as minimally improved or better for 16 cases. The present findings suggest that the atypical antipsychotics Olanzapine and Risperidone are well tolerated by patients with intellectual disability and psychiatric disorders, and are broadly effective against target symptoms.